Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi

Abstract

The RTS,S/AS01 malaria vaccine will undergo a pilot vaccination study in sub-Saharan Africa beginning in 2019. RTS,S/AS01 Phase III trials reported an efficacy of 28.3% (children 5-17 months) and 18.3% (infants 6-12 weeks), with substantial variability across study sites. We postulated that the relatively low efficacy of the RTS,S vaccine and variability across sites may be due to lack of T-cell epitopes in the vaccine antigen, and due to the HLA distribution of the vaccinated population, and/or due to 'immune camouflage', an immune escape mechanism. To examine these hypotheses, we used immunoinformatics tools to compare T helper epitopes contained in RTS,S vaccine antigens with Plasmodium falciparum circumsporozoite protein (CSP) variants isolated from infected individuals in Malawi. The prevalence of epitopes restricted by specific HLA-DRB1 alleles was inversely associated with prevalence of the HLA-DRB1 allele in the Malawi study population, suggesting immune escape. In addition, T-cell epitopes in the CSP of strains circulating in Malawi were more often restricted by low-frequency HLA-DRB1 alleles in the population. Furthermore, T-cell epitopes that were highly conserved across CSP variants in Malawi possessed TCR-facing residues that were highly conserved in the human proteome, potentially reducing T-cell help through tolerance. The CSP component of the RTS,S vaccine also exhibited a low degree of T-cell epitope relatedness to circulating variants. These results suggest that RTS,S vaccine efficacy may be impacted by low T-cell epitope content, reduced presentation of T-cell epitopes by prevalent HLA-DRB1, high potential for human-cross-reactivity, and limited conservation with the CSP of circulating malaria strains.

Defeating malaria: new weapons against one of our deadliest foes

“…Optimal protection from immunisation requires a four-dose schedule. 12,19 But the results suggest that the long-sought after vaccines are possible. Indeed, about 20 vaccines based on whole organisms or well-characterised antigens are in clinical trials.…”

Identification and Immune Assessment of T Cell Epitopes in Five Plasmodium falciparum Blood Stage Antigens to Facilitate Vaccine Candidate Selection and Optimization

“…This homology analysis is performed using the JanusMatrix tool, which examines human sequence similarity with respect to the HLA and T cell receptor (TCR) faces of an epitope to flag sequences that could potentially elicit undesired autoimmune or Treg responses due to homology with sequences encoded by the human genome (32). The JanusMatrix (human homology) score of a given amino acid sequence indicates the number of potential immunosuppressive response triggers or flags, with higher JanusMatrix scores indicating a bias towards immune tolerance (33). Note that additional information concerning the role of the Treg repertoire in maintenance of self-tolerance can be found in Feng et al (34).…”

Bridging Computational Vaccinology and Vaccine Development Through Systematic Identification, Characterization, and Downselection of Conserved and Variable Circumsporozoite Protein CD4 T Cell Epitopes From Diverse Plasmodium falciparum Strains

“…This homology analysis is performed using the JanusMatrix tool, which examines human sequence similarity with respect to the HLA and T cell receptor (TCR) faces of an epitope to flag sequences that could potentially elicit undesired immunosuppressive responses due to homology with sequences encoded by the human genome (31). The JanusMatrix (human homology) score of a given amino acid sequence indicates the number of potential immunosuppressive response triggers or flags, with higher JanusMatrix scores indicating a bias towards immune tolerance (32). Ninety-five percent of randomly generated predicted ligands to HLA-DRB1 supertype alleles have JanusMatrix (human homology) scores between zero and two.…”